{
  "meta": {
    "timestamp": "2025-01-06T14:16:46.056827",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Viridian Therapeutics Inc.",
      "symbol": "VRDN",
      "analysis": {
        "historical": {
          "risk_score": 70,
          "key_risks": [
            "Regulatory and Clinical Trial Risks: Potential delays or rejections in regulatory approvals for VRDN-001, VRDN-002, and VRDN-003.",
            "Financial Sustainability: Heavy reliance on external funding with a reported quarterly loss of $1.15 per share in Q3 2024.",
            "Competitive Landscape: High competition in the biopharmaceutical industry with larger companies and other biotechs developing similar therapies.",
            "Market Volatility: Significant stock price fluctuations, reflecting the high-risk nature of clinical-stage biotech investments."
          ],
          "controversies": [],
          "environmental_issues": [],
          "social_issues": [
            "Ethical and Social Impact: Focus on serious and rare diseases, such as thyroid eye disease (TED), addressing significant unmet medical needs."
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. - Viridian Therapeutics Highlights Recent ...",
              "snippet": "WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the first quarter ending March 31, 2024. \"It has been a remarkable first quarter of execution as we made progress across ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:18.637025+00:00",
              "published_date": null,
              "source_hash": "5cce32dd4e93f7029b3aac1e25a2c806"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. - Viridian Therapeutics Announces ...",
              "snippet": "WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that enrollment is complete in THRIVE-2, its phase 3 clinical trial for VRDN-001 in patients with chronic TED. THRIVE-2 enrolled 188 patients globally and exceeded the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:18.637129+00:00",
              "published_date": null,
              "source_hash": "339d7f2c2c6361e95550de05c31d6c5a"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics Announces FDA Clearance of Investigational New ...",
              "snippet": "Phase 1/2 proof of concept trial for VRDN-001 is expected to report top line clinical data in the second quarter of 2022 WALTHAM, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:18.637144+00:00",
              "published_date": null,
              "source_hash": "ff867adf6211b52f26e8356652c0593f"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. - Viridian Therapeutics Announces Positive ...",
              "snippet": "- Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p < 0.0001) - - THRIVE-2 is the first global phase 3 study in patients with chronic TED to demonstrate a statistically significant and clinically meaningful 56% diplopia responder rate (placebo-adjusted rate ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:27.820009+00:00",
              "published_date": null,
              "source_hash": "5ddf72c2d5672a03a46e33e09cd5c212"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing ...",
              "snippet": "Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:18.637165+00:00",
              "published_date": null,
              "source_hash": "55b732a1fa86a984a5077dcfff68f849"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics Announces FDA Clearance of - GlobeNewswire",
              "snippet": "About Viridian Therapeutics, Inc. ... the duration and impact of regulatory delays in our clinical programs; manufacturing risks; competition from other therapies or products; the timing of and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:18.637174+00:00",
              "published_date": null,
              "source_hash": "f13dbb4b5121524718c8c8a4e9dc3fa8"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. (VRDN) - Yahoo Finance",
              "snippet": "WALTHAM, Mass., December 13, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:18.637183+00:00",
              "published_date": null,
              "source_hash": "c66f6039dcabb28429452955b92c72ae"
            },
            {
              "url": "",
              "title": "Our Pipeline - Viridian Therapeutics, Inc.",
              "snippet": "We have created a robust pipeline of differentiated investigational therapeutic candidates for well-validated targets.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:23.774734+00:00",
              "published_date": null,
              "source_hash": "38cb08473182cb57eedf72ed15055ee8"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics Inc | Reuters",
              "snippet": "Viridian Therapeutics said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the first ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:18.637200+00:00",
              "published_date": null,
              "source_hash": "4ff64198d37244b5371f4572ee2b3292"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. - Viridian Therapeutics Announces Positive ...",
              "snippet": "- Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder rate (PRR) of 70% and a placebo-adjusted PRR of 64% (p < 0.0001) - - All secondary endpoints were highly statistically significant (p < 0.0001), with clinically meaningful patient ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:18.637210+00:00",
              "published_date": null,
              "source_hash": "5be068c404a717484f7b43ddcae2895a"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics Inc (VRDN) Stock Sees Market Value Hit $1.57 billion: What Are the Implications?",
              "snippet": "Wells Fargo has recently reduced Viridian Therapeutics Inc (VRDN) stock to Equal Weight rating, as announced on December 19, 2024, according to Finviz. Earlier, on November 25, 2024, TD Cowen had initiated the stock to Buy.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:30.356893+00:00",
              "published_date": "2025-01-03T14:56:00+00:00",
              "source_hash": "5a9b6ece1f35d77502e1edc3d007779e"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics (NASDAQ:VRDN) Shares Down 3.4% - Here's Why",
              "snippet": "Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) were down 3.4% during trading on Tuesday . The stock traded as low as $18.77 and last traded at $19.01. Approximately 81,134 shares traded hands during mid-day trading, a decline of 93 ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:22.114500+00:00",
              "published_date": "2024-12-25T23:59:00+00:00",
              "source_hash": "80af55afbeba9a75c6bc50c04520da5d"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates",
              "snippet": "Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:30.356881+00:00",
              "published_date": "2024-12-11T06:30:00+00:00",
              "source_hash": "3dcdb795be1ceedda0aebbb9c87a971c"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
              "snippet": "Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:22.114524+00:00",
              "published_date": "2024-12-04T00:00:00+00:00",
              "source_hash": "8ea45800ad8518aff6263f41d2ebda44"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. (VRDN) stock forecast and price target",
              "snippet": "Find the latest Viridian Therapeutics, Inc. VRDN analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:16:22.114533+00:00",
              "published_date": "2024-03-29T13:05:00+00:00",
              "source_hash": "21b8539c62396d03f0778c468b9a4a46"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. - Viridian Therapeutics Announces Positive ...",
              "snippet": "WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE phase 3 clinical trial of VRDN-001, now known as veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:23.774608+00:00",
              "published_date": null,
              "source_hash": "512c5532530016d37d0553f6513426e4"
            },
            {
              "url": "",
              "title": "Clinical Trials - Viridian Therapeutics, Inc.",
              "snippet": "Viridian Therapeutics is focused on engineering and developing potential best-in-class medicines for people living with autoimmune and rare diseases. ... Clinical Trials. View. Featured Trials. THRIVE. Active Thyroid Eye Disease. Global Phase 3 trial to evaluate the efficacy and safety of VRDN-001 in patients with active TED .",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:23.774710+00:00",
              "published_date": null,
              "source_hash": "4f90f6b23702d8bac07cd5522357d6e0"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics Announces Positive Topline Results from ...",
              "snippet": "WALTHAM, Mass., December 16, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:23.774723+00:00",
              "published_date": null,
              "source_hash": "9796ec10d7a53e4ff49d5c9d81118f3b"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics sees stock soar after Phase III TED success",
              "snippet": "Viridian Therapeutics's stock has jumped after a Phase III trial of veligrotug met all endpoints and was well tolerated in patients with chronic thyroid eye disease (TED). The THRIVE-2 (NCT05176639) global Phase III study investigated the intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody in patients with TED.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:27.820170+00:00",
              "published_date": null,
              "source_hash": "d878a6291889d4548a1a83897efa4624"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. - Investors & Media",
              "snippet": "The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:23.774753+00:00",
              "published_date": null,
              "source_hash": "70fa2cd267a99832d47fd3eb2d2a6dfc"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics",
              "snippet": "Viridian Therapeutics is leveraging core expertise in antibody discovery to develop optimized treatments for rare autoimmune conditions. Skip Navigation. Toggle Navigation. ... CLINICAL TRIALS. Framing the future of autoimmune diseases. Placing the impacts of thyroid eye disease (TED) into perspective. MORE ABOUT TED.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:23.774761+00:00",
              "published_date": null,
              "source_hash": "4124ded30a6e7efd800ee5d7b8ac70c7"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics' stock jumps after Phase III trial met all endpoints",
              "snippet": "Viridian Therapeutics's veligrotug has met all primary and secondary endpoints in a Phase III trial in active thyroid eye disease (TED). Previously known as VRDN-001, veligrotug won in the Phase III THRIVE trial (NCT05176639). It also boasted positive safety data in patients with TED, which is also known as Graves' disease.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:27.820142+00:00",
              "published_date": null,
              "source_hash": "b8dea96b9bd7ee15fd0a0f38748458d9"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics announces THRIVE-2 trial met primary, secondary ...",
              "snippet": "Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:23.774779+00:00",
              "published_date": null,
              "source_hash": "c2a555aeac818ab848666323b91c7081"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics Poised for Impact Amid Mixed Clinical Trial and ...",
              "snippet": "As December 16, 2024 approaches, all eyes will be on Viridian Therapeutics, Inc. (NASDAQ: VRDN) as the biopharmaceutical company prepares to unveil the topline results from its THRIVE-2 Phase 3 clinical trial evaluating its promising product, veligrotug, for the treatment of chronic Thyroid Eye Disease (TED). This pivotal moment represents a crucial juncture for Viridian, as success in this ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:23.774787+00:00",
              "published_date": null,
              "source_hash": "283f5cf767a0377019fd76af319b89df"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data",
              "snippet": "Shares of Viridian Therapeutics surged nearly 18% at the open on Monday to a nearly three-week high after the company reported promising trial data for its experimental drug veligrotug ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:26.172715+00:00",
              "published_date": "2024-12-16T14:58:00+00:00",
              "source_hash": "757f9ecb32e893ca64767739d644c51e"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. (VRDN)",
              "snippet": "its phase 3 clinical trial for VRDN-001 in patients with chronic TED. WALTHAM, Mass., June 11, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:26.172800+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "7cbcc8f2bd22b8f17c57dc4baa916947"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics (VRDN): A Small-Cap Biotech with Promising Clinical Results",
              "snippet": "Viridian Therapeutics, Inc. (NASDAQ:VRDN) on September 10, announced positive results for its Phase 3 THRIVE clinical trial for Veligrotug. The results showed that after a week 70% of patients ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:26.172815+00:00",
              "published_date": "2024-10-23T12:58:00+00:00",
              "source_hash": "6e9ee10a515836fe011ea89b5e81ebb2"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease",
              "snippet": "December 16, 2024--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ ... positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:26.172825+00:00",
              "published_date": "2024-12-16T07:00:00+00:00",
              "source_hash": "cb219f20f746e70bae2a8cd853d8ff76"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics Achieves Milestone in Phase 3 Trial",
              "snippet": "The trial met all endpoints, showing significant improvements in proptosis, diplopia, and clinical activity ... More about Viridian Therapeutics Viridian Therapeutics, Inc. is a biopharmaceutical ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:16:26.172835+00:00",
              "published_date": "2024-12-16T06:46:00+00:00",
              "source_hash": "e8ce2ca6b9defe03313ec695b47b05a7"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. - Viridian Therapeutics Announces ...",
              "snippet": "- THRIVE-2 exceeded its enrollment target due to patient demand; 188 patients enrolled with approximately 40% from US sites - - THRIVE topline readout in patients with active TED on track for September 2024 - - THRIVE-2 topline readout on track for year-end 2024 - Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:27.820116+00:00",
              "published_date": null,
              "source_hash": "b1a64f4ac484e5632df07e561b411266"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. - Viridian Therapeutics Highlights Recent ...",
              "snippet": "WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today reported recent business highlights and financial results for the second quarter ending June 30, 2024. \"Our team continues to execute across the board as shown by the progress we have ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:27.820131+00:00",
              "published_date": null,
              "source_hash": "eea0d232ff60cc39b4798dc29e44c333"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. (LON: 0K1R) - Stock Analysis",
              "snippet": "Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseas...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:27.820151+00:00",
              "published_date": null,
              "source_hash": "cb136f94423cd4fdd85d049a453f4c56"
            },
            {
              "url": "",
              "title": "Our Company - Viridian Therapeutics, Inc.",
              "snippet": "The Viridian Therapeutics team's expertise in antibody discovery & engineering, has created a robust pipeline of therapeutic candidates ... improved safety and tolerability and convenient delivery and administration for patients. Our thyroid eye disease program is an example of our drug development strategy in action, aiming to improve upon ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:27.820161+00:00",
              "published_date": null,
              "source_hash": "fef6dc5d163f64e630e892c66ea59151"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics",
              "snippet": "Viridian Therapeutics is leveraging core expertise in antibody discovery to develop optimized treatments for rare autoimmune conditions. ... Motivated to improve patient care with optimized therapeutics. PATIENT COMMUNITY. CLINICAL TRIALS. Framing the future of autoimmune diseases. Placing the impacts of thyroid eye disease (TED) into ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:27.820180+00:00",
              "published_date": null,
              "source_hash": "859b2ce66ed17963a64fa0eb359ca9fd"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. (VRDN) Company Profile & Overview - Stock ...",
              "snippet": "Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:27.820190+00:00",
              "published_date": null,
              "source_hash": "b689c5fb242f6f87819c0e6309d8d29f"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics Company Profile 2024: Stock Performance ...",
              "snippet": "Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:27.820200+00:00",
              "published_date": null,
              "source_hash": "b813cdf986d0432f4432bafa80b11da4"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics, Inc. (VRDN)",
              "snippet": "WALTHAM, Mass., December 16, 2024--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:30.356801+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "afbcf6288ba19246bad298eaaaefb033"
            },
            {
              "url": "",
              "title": "Viridian stock soars 25% on Phase 3 data for veligrotug",
              "snippet": "Viridian Therapeutics (NASDAQ:VRDN) shares shot up 25% in early trading Monday after the company reported positive topline results from a Phase 3 study of its drug veligrotug in the treatment of ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:30.356904+00:00",
              "published_date": "2024-12-16T15:40:00+00:00",
              "source_hash": "f83e193d677b17d67a41f35d278e4cbe"
            },
            {
              "url": "",
              "title": "Viridian Therapeutics' Veligrotug Shows Best-in-Class Potential in Phase 3 THRIVE-2 Trial for Chronic TED",
              "snippet": "The trial successfully met all primary and secondary endpoints, indicating significant efficacy and safety ... Viridian Therapeutics (VRDN) Company Description: Miragen Therapeutics, Inc. is ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Viridian Therapeutics Inc. Viridian Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:16:30.356913+00:00",
              "published_date": "2024-12-16T09:04:00+00:00",
              "source_hash": "39a77be4477c04baf57fe24437d73e94"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Viridian Therapeutics Inc. regulatory approval delays",
              "rationale": "Investigate potential delays or issues in obtaining regulatory approvals for its key products",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Viridian Therapeutics Inc. clinical trial failures",
              "rationale": "Examine any reported failures or setbacks in clinical trials for VRDN-001, VRDN-002, or VRDN-003",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Viridian Therapeutics Inc. patient safety concerns",
              "rationale": "Look for any reports or controversies related to patient safety or adverse effects in clinical trials",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:16:46.056835",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}